Last week, on November 14, 2024, I had the privilege of attending the NIH Myositis Common Data Elements (CDEs) Consensus Conference at NIH in Bethesda, MD. This pivotal meeting brought together researchers, clinicians, and patient representatives like myself to advance the standardization of data collection for myositis research. As the MSU representative I am excited to share how this effort aligns with our patient-centered objectives and how we can continue to contribute to this groundbreaking work.
Patient-Centered Objectives
The overarching goal of the NIH project is to develop interoperable, standardized tools for myositis research. This initiative will help improve data sharing, streamline clinical trials, and ultimately enhance patient outcomes. At MSU, we believe in empowering patients by prioritizing their perspectives in research efforts. This philosophy guides our involvement in the following goals of the project:
Ensuring Patient Voices Shape Research
During the meeting, I advocated for the inclusion of patient-reported outcome measures (PROMs) and quality-of-life assessments. These tools reflect the lived experiences of patients with myositis and are critical to understanding how the disease impacts daily life. MSU will continue to champion the integration of PROMs into the core set of CDEs to ensure that patient needs remain at the center of myositis research.
Advancing Accessibility and Usability of Research Tools
One of the workshop’s key outcomes was the endorsement of common data elements for myositis disease activity measures. As a voting member of the project, I look forward to ensuring that these tools are not only scientifically robust but also accessible to patients and caregivers. This means developing clear instructions, fostering understanding, and encouraging use beyond clinical settings.
Prioritizing Functional and Strength Measures
Understanding the physical challenges faced by individuals with myositis, I emphasized the importance of prioritizing forms related to physical function, strength, and daily living activities. These measures provide valuable insights into the disease’s real-world impact and are instrumental in designing patient-centered interventions.
Collaborating on Coding Initiatives
As part of the next phase, I am volunteering for the coding project, which focuses on refining and organizing data from validated study forms. This work is essential for creating a comprehensive repository in the National Library of Medicine’s CDE repository. By contributing to this effort, I aim to ensure the data reflects the priorities and diversity of patient experiences.
Shaping the Future of Myositis Research
The workshop concluded with discussions on prioritizing additional study forms for CDE creation. With 43 potential forms under review, I highlighted the need to bring more forms that address pain and fatigue as well as falling risks in IBM.
Manuel Lubinus- Chief Science Officer MSU
Group Room at NIH
Virtual attendees including patient representatives
At MSU, we believe in the power of patient advocacy and engagement.
If you have thoughts or experiences you’d like to share, please reach out.
On March 1, 2024, MSU's was honored to participate in the 11th Annual Rare Disease Symposium held by the Alabama Rare Disease Advisory Council at the University of Alabama in Birmingham (UAB). MSU's Vice-President Benita Moyers (Anti-MDA5 DM) presented our abstract Anti-MDA5 Dermatomyositis Patient-Led Research Survey: Unveiling Symptoms, Treatments and Trial Attitudes. Dr. Stephen Moore (DM) presented our abstract Burden of Disease in Idiopathic Inflammatory Myopathies: First Perspectives From a Patient-Led Research Study. Stephen also participated in the five minute Lightning Talks where he discussed the Burden of Disease study. They were joined by one of our medical advisors, Dr. Lauren Graham, from UAB.
On February 1, 2024, the Adult Dermatomyositis Externally-Led Drug-Development Meeting official website launched. Visitors can learn more about the EL-PFDD process, register for the event, submit stories, and more. We encourage you to visit the website by clicking the image below.
MSU Collaborates on Biodigit IBM Study
Biodigit has recently started the BioDigit IBM clinical study, and formed a new partnership with the Myositis Support & Understanding.
The study aims to collect longitudinal clinical and wearable sensor data using PAMSysTM and PAMSys ULMTM sensors for precision actigraphy and monitoring upper limb function during activities of daily living.
The clinical study is in collaboration with Mazen Dimachkie, MD at the University of Kansas Medical Center and Myositis Support & Understanding. Recruitment for BioDigit IBM commenced in December 2023, and the study is set to complete its recruitment before the end of this month.
The first ever Externally-Led Patient-Focused Drug Development Town Hall on Adult Dermatomyositis will be held June 7, 2024. MSU and TMA are partnering on this special virtual meeting, designed to bring the patient voice to the FDA , other government agencies, doctors, scientists and medical product developers. Mark your calendars and stay tuned for more information and the launch of the our community website in Jan. 2024..........
View EL-PFDD for more general information.